Puma Biotechnology, Inc. (PBYI)
10.22
+0.39
(+3.97%)
USD |
NASDAQ |
Oct 19, 16:00
10.22
0.00 (0.00%)
After-Hours: 20:00
Puma Biotechnology Enterprise Value : 413.25M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 413.25M |
| October 15, 2026 | 448.51M |
| October 14, 2026 | 432.16M |
| October 13, 2026 | 428.07M |
| October 12, 2026 | 436.76M |
| October 09, 2026 | 436.76M |
| October 08, 2026 | 420.41M |
| October 07, 2026 | 412.23M |
| October 06, 2026 | 396.39M |
| October 05, 2026 | 405.08M |
| October 02, 2026 | 396.90M |
| October 01, 2026 | 413.76M |
| September 30, 2026 | 418.36M |
| September 29, 2026 | 410.70M |
| September 28, 2026 | 412.74M |
| September 25, 2026 | 410.19M |
| September 24, 2026 | 412.74M |
| September 23, 2026 | 385.15M |
| September 22, 2026 | 412.74M |
| September 21, 2026 | 400.99M |
| September 18, 2026 | 401.50M |
| September 17, 2026 | 397.41M |
| September 16, 2026 | 390.77M |
| September 15, 2026 | 383.61M |
| September 14, 2026 | 377.99M |
| Date | Value |
|---|---|
| September 11, 2026 | 376.97M |
| September 10, 2026 | 379.53M |
| September 09, 2026 | 373.39M |
| September 08, 2026 | 390.77M |
| September 04, 2026 | 398.94M |
| September 03, 2026 | 391.79M |
| September 02, 2026 | 406.10M |
| September 01, 2026 | 388.72M |
| August 31, 2026 | 376.46M |
| August 28, 2026 | 373.90M |
| August 27, 2026 | 383.10M |
| August 26, 2026 | 379.01M |
| August 25, 2026 | 387.19M |
| August 24, 2026 | 376.97M |
| August 21, 2026 | 383.10M |
| August 20, 2026 | 376.46M |
| August 19, 2026 | 395.88M |
| August 18, 2026 | 383.10M |
| August 17, 2026 | 361.64M |
| August 14, 2026 | 362.15M |
| August 13, 2026 | 356.02M |
| August 12, 2026 | 365.73M |
| August 11, 2026 | 359.08M |
| August 10, 2026 | 355.00M |
| August 07, 2026 | 366.24M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anika Therapeutics, Inc. | 254.23M |
| Arcutis Biotherapeutics, Inc. | 3.495B |
| Olema Pharmaceuticals, Inc. | 118.03M |
| ACADIA Pharmaceuticals, Inc. | 2.409B |
| Alnylam Pharmaceuticals, Inc. | 30.68B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 8.189M |
| Revenue (Quarterly) | 56.50M |
| Total Expenses (Quarterly) | 48.31M |
| EPS Diluted (Quarterly) | 0.1557 |
| Gross Profit Margin (Quarterly) | 77.92% |
| Profit Margin (Quarterly) | 14.49% |
| Earnings Yield | 5.05% |
| Operating Earnings Yield | 5.79% |
| Normalized Earnings Yield | 5.053 |